TGFB1 and reactive cutaneous fibrous lesion: Also attenuate other outcomes, such as Collagen Type I [SMD = -4.39, 95%CI: -5.96-2.81], Collagen Type III [SMD = -5.19, 95%CI: -6.93-3.44], migration and proliferation of skin fibroblasts, and the expression of Transforming Growth Factor-β1 (TGF-β1) and α-smooth muscle actin (α-SMA) in scar tissue.<h4>Conclusion</h4>The meta-analysis supports the therapeutic potential of MSC-EVs in the treatment of keloids and hypertrophic scars, as demonstrated in preclinical animal models.